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Expression analysis in a rat psychosis model identiﬁes novel
candidate genes validated in a large case–control sample of
schizophrenia
A Ingason1, I Giegling1, AM Hartmann1, J Genius2, B Konte1, M Friedl1, Schizophrenia Working Group of the Psychiatric Genomics
Consortium (PGC)9, S Ripke3, PF Sullivan4, D St. Clair5, DA Collier6, MC O’Donovan7, K Mirnics8 and D Rujescu1
Antagonists of the N-methyl-D-aspartate (NMDA)-type glutamate receptor induce psychosis in healthy individuals and exacerbate
schizophrenia symptoms in patients. In this study we have produced an animal model of NMDA receptor hypofunction by
chronically treating rats with low doses of the NMDA receptor antagonist MK-801. Subsequently, we performed an expression study
and identiﬁed 20 genes showing altered expression in the brain of these rats compared with untreated animals. We then explored
whether the human orthologs of these genes are associated with schizophrenia in the largest schizophrenia genome-wide
association study published to date, and found evidence for association for 4 out of the 20 genes: SF3B1, FOXP1, DLG2 and VGLL4.
Interestingly, three of these genes, FOXP1, SF3B1 and DLG2, have previously been implicated in neurodevelopmental disorders.
Translational Psychiatry (2015) 5, e656; doi:10.1038/tp.2015.151; published online 13 October 2015
INTRODUCTION
Schizophrenia is a debilitating major psychiatric disorder1
associated with severely reduced quality of life and reduced life
expectancy among those affected.2,3 The disorder is characterized
by various behavioral symptoms both positive (including halluci-
nations, formal thought disorder and paranoia) and negative (incl.
apathy, social withdrawal and reduced mood), as well as cognitive
symptoms (incl. impaired memory and attention span).1 A major
factor contributing to the reduced quality of life and reduced life
expectancy in schizophrenia is its resistance to treatment.
Although antipsychotic medications can alleviate some of the
symptoms in patients, notably the positive symptoms, there is no
cure available for schizophrenia, and most patients who respond
to current treatments fail to cope fully in society, as the negative
and cognitive symptoms are poorly treated. Whereas conventional
antipsychotics act by blocking dopamine receptors, the last two
decades have seen growing evidence linking defects in glutama-
tergic neurotransmission to schizophrenia pathology.4,5 The
primary evidence in this regard is the observation that non-
competitive antagonists of the N-methyl-D-aspartate (NMDA)-type
glutamate receptor, including ketamine and phencyclidine,
exacerbate manifestations of schizophrenia in patients and induce
positive and negative symptoms as well as cognitive impairments
in healthy individuals.6–8 Rodent animal models using MK801 as
an antagonist show supporting evidence to the NMDA receptor
hypofunction model in schizophrenia on a molecular, cellular,
functional and behavioral level including altered expression of
NMDA receptor subunits, decrease in the relative number of a
speciﬁc subset of GABAergic interneurons, evidence of altered
recurrent inhibition of pyramidal cells and cognitive deﬁcits
associated with hippocampal dysfunction, resembling ﬁndings in
patients.9
Grunze et al.10 found that GABAergic interneurons in the
hippocampus are especially sensitive to NMDA receptor antago-
nists and postulated that reduction in GABAergic inhibition could
mediate the cognitive impairment seen in schizophrenia or
induced in healthy subjects by ketamine and other partial NMDA
antagonists, respectively. This hypothesis found some support in
two functional brain-imaging studies showing reduced hippo-
campal activation in schizophrenia subjects while performing a
memory task because of a high hippocampal baseline activity.11,12
Harris et al.13 found that adult mice that had been treated
neonatally with MK-801, an NMDA receptor antagonist, had
reduced volume and neuronal number within the hippocampus,
altered hippocampal NMDA receptor (NR1 subunit) expression
and showed prepulse inhibition deﬁcits and increased locomotor
activity, reminiscent of alterations reported in schizophrenia.
Frolich and Van Horn14 provide a recent review of the utility of the
ketamine model of schizophrenia and the critical role of
GABAergic interneurons.
The etiology of schizophrenia involves a strong genetic
component with heritability estimates ranging from 60 to
80%.15,16 Prominent candidate genes, identiﬁed by linkage and
ﬁne-mapping studies in the early 2000s and believed to be
involved in schizophrenia pathology, include several members of
the glutamatergic signaling network, such as Neuregulin 1 (ref. 17)
and its receptor ErbB4 (ref. 18) that regulate the activity of NMDA
1Department of Psychiatry, University of Halle-Wittenberg, Halle, Germany; 2Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany; 3Analytical and
Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; 4Department of Genetics, University of North Carolina at Chapel Hill,
Chapel Hill, NC, USA; 5Department of Mental Health, University of Aberdeen, Aberdeen, UK; 6King's College London, Social, Genetic and Developmental Psychiatry Centre,
Institute of Psychiatry, London, UK; 7Institute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University,
Cardiff, UK and 8Department of Psychiatry, Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, TN, USA. Correspondence: Professor
Dr D Rujescu, Department of Psychiatry, Psychotherapy and Psychosomatics, Martin-Luther-University Halle-Wittenberg, Julius-Kühn-Strasse 7, Halle 06112, Germany.
E-mail: dan.rujescu@uk-halle.de
9Full list of contributors to the Psychiatric Genetics Consortium is provided in Supplementary Information.
Received 16 February 2015; revised 16 June 2015; accepted 14 July 2015
Citation: Transl Psychiatry (2015) 5, e656; doi:10.1038/tp.2015.151
www.nature.com/tp
receptors at postsynaptic sites.19,20 The introduction of single-
nucleotide polymorphism microarrays has pushed forward the
ﬁeld of genetics in the last years, as genotypes from hundreds of
thousands of markers across the genome can be obtained from a
single assay. This has led to the identiﬁcation of several novel
genes involved in schizophrenia etiology, including ZNF804A,21,22
NRGN,23 TCF4,23 VRK2 (ref. 24) several genes in the major
histocompatibility complex region on 6p,23,25–26 and, most
recently, by combining results from 52 case–control studies in a
meta-analysis including over 30 000 affected and even more
controls, over 100 novel schizophrenia-associated loci were
identiﬁed.27 These microarrays have also allowed the discovery
of genomic copy number variations (CNVs) that associate with
schizophrenia, implicating further genes such as NRXN1,28 CHRNA7
(refs. 29,30) and CYFIP1 (ref. 29) in the pathology of the disorder.
Here, we have performed an expression study on rats
chronically treated with low doses of the NMDA receptor
antagonist MK-801, and identiﬁed a set of 20 genes differentially
expressed in the hippocampus of these rats compared with
controls. Hypothesizing that the orthologs of these genes are
involved in schizophrenia pathophysiology in humans, we then
investigated the association of markers mapping to the human
orthologs of these genes in the genome-wide association study
(GWAS) results for schizophrenia from the large Psychiatric
Genetics Consortium (PGC) meta-analysis.27 In addition, we
searched a gene-wide typed schizophrenia case–control sample
for CNVs overlapping exons at these 20 loci.
MATERIALS AND METHODS
Animal samples
Male Long Evans rats (n= 24; age 35± 1 days; initial weight 121–148 g)
were housed in groups of four in cages in a temperature-controlled room
(23 °C), with a 12/12-h light/dark cycle and with food and water provided
ad libitum. They received daily intraperitoneal injections (10ml kg− 1 body
weight, 0.9% saline as vehicle) of either 0.02mg kg− 1 body weight
(+)-MK-801 (n= 12) or 0.9% saline (placebo, n= 12) for 20 days during the
light phase. While under deep CO2 anesthesia, rats were killed by
decapitation 24 h following the last drug administration. Further details are
provided in Rujescu et al.31 All manipulations were performed in strict
accordance with the current versions of the US and German Law for the
Protection of Animals (approval ID: 209.1/211-2531-78/03 Regierung von
Oberbayern, Munich, Germany).
Expression analysis. Hippocampi were isolated from brains of MK-801-
treated animals (n=12) and controls (n= 12), shock-frozen in liquid
nitrogen and immediately stored at –80 °C until further processing. Tissue
(30–80mg) was homogenized in QIAzol Lysis Reagent (Qiagen, Hilden,
Germany) using ultra thurrax. Total RNA was extracted with the RNeasy
Lipid Tissue Mini Kit (Qiagen) according to the manufacturer’s instructions
and stored at –80 °C. RNA concentration and quality was estimated using a
UV spectrometer and an ethidium bromide-stained agarose gel. Equal
amounts of RNA of three animals conferring to one experimental group
were pooled, and 4.07 ± 0.7 μg RNA of each of the resulting eight pools
(four pools of three MK-801-treated animals and four pools of three control
animals) hybridized to one array (GeneChip Rat Genome 230 2.0 Array,
Affymetrix, Santa Clara, CA, USA). Expression data were normalized using
the robust multiarray average method in GenePattern,32 and P-values were
established using a two-tailed t-test.
Human samples
PGC sample. The PGC schizophrenia GWAS sample includes 34 241
schizophrenia cases and 45 604 control individuals from 49 different sites,
and 1235 parent affected-offspring trios. Details of the sample and the PGC
schizophrenia GWAS are provided in Ripke et al.27
Munich sample
Schizophrenia patients: In total, 625 (394 men and 231 women, aged
18–70) individuals with schizophrenia were ascertained from the Munich
area in Germany. All were of German (both parents German) or Central
European (either or both parents non-German Central European) descent,
and had a diagnosis of schizophrenia according to both the Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) and Interna-
tional Statistical Classiﬁcation of Diseases and Related Health Problems,
10th revision (ICD-10). Detailed medical and psychiatric histories were
collected, including the Structured Clinical Interview for DSM-IV (SCID), to
evaluate lifetime Axis I and II diagnoses.33,34 Four physicians and one
psychologist rated the SCID interviews and all measurements were double-
rated by a senior researcher. Exclusion criteria included a history of head
injury or neurological diseases. All case participants were outpatients or
stable in-patients.
Healthy controls: In total, 539 (246 men and 293 women, aged 19–72)
unrelated volunteers of German descent (that is, both parents German)
were randomly selected from the general population of Munich, Germany,
and contacted by mail. To exclude subjects with central neurological
diseases and psychotic disorders or subjects who had ﬁrst-degree relatives
with psychotic disorders, several screenings were conducted before the
volunteers were enrolled in the study. First, subjects who responded were
screened by phone for the absence of neuropsychiatric disorders. Second,
detailed medical and psychiatric histories were assessed for both
themselves and their ﬁrst-degree relatives by using a semistructured
interview. Third, if no exclusion criteria were fulﬁlled, they were invited to a
comprehensive interview including the Structured Clinical Interview for
DSM-IV (SCID I and SCID II)33,34 to validate the absence of any lifetime
psychotic disorder. In addition, the Family History Assessment Module35 was
conducted to exclude psychotic disorders among ﬁrst-degree relatives.
Furthermore, a neurological examination was conducted to exclude subjects
with current central nervous system impairment. In the case that the
volunteers were older than 60 years, the Mini Mental Status Test36 was
performed to exclude subjects with possible cognitive impairment.
Written informed consent was obtained from all subjects after a detailed
and extensive description of the study, which was approved by the local
ethics committee and carried out in accordance to the ethical standards
laid down in the Declarations of Helsinki.
Genotyping: The Munich samples were genotyped on the Illumina
HumanHap300 arrays. Blood was drawn and DNA isolated following
standard procedures as described in Stefansson et al.29 and Need et al.37
The majority of samples (n=790; 437 cases and 353 controls) were
genotyped as part of a schizophrenia case–control GWAS described in
detail in Need et al.37 Another 374 samples (188 cases and 186 controls)
were genotyped as part of the SGENE study, a multicenter collaboration to
ﬁnd schizophrenia susceptibility genes; the genotyping of these samples is
described in detail in Stefansson et al.29 We used the PennCNV algorithm38
to derive CNV calls from the Munich sample. The list of CNV calls was then
reﬁned by removing calls from sample outliers as well as calls spanning
fewer than 10 consecutive markers, and by joining calls occurring in the
same sample close-by on the same chromosome if the total length of the
interval(s) between the calls was less than 50% of their combined length
including the interval(s).
RESULTS
To deﬁne a list of truly differentially expressed genes between the
MK801-treated and control animals, we ﬁrst performed an
experimental analysis at various levels of stringency based on
|ALR| (absolute average log2 ratio; magnitude of change) and P
(probability of random occurrence). For each level of stringency
we derived the number of transcripts differentially expressed in
the real experiment (e1–e2–e3–e4 versus c1–c2–c3–c4, where e1–4
and c1–4 denote the four pools of each three MK801-treated
animals and four pools of three control animals, respectively) and
the number of transcripts differentially expressed in three
permutation comparisons (Boot 1, c1–c2–e3–e4 versus c3–c4–
e1–e2; Boot 2, c1–c3–e2–e4 versus c2–c4–e1–e3; Boot 3, c1–c4–
e2–e3 versus c2–c3–e1–e4). The logic here is that if the
manipulation is the biggest contributor to the effect, the effect
will be canceled out in the permutation comparisons, whereas if
other factors are responsible for most of the effect the
permutation comparisons will produce equally many differentially
expressed transcripts as the real experiment. We used the results
to calculate a false discovery rate (FDR), and accordingly chose to
use the stringency where the FDR is lowest; the results are
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summarized in Table 1. Using |ALR|40.585 (corresponding to 50%
change) and Po0.05 gave the lowest FDR, at 34.5%, from 74
differentially expressed transcripts (Table 1 and Figure 1).
To further reﬁne this list, we compared all four MK801-treated
animals individually against all four control animals (in total 16
comparisons), and considered only those transcripts reaching 50%
change (|ALR| = 0.585) in at least nine comparisons as truly
differentially expressed; this yielded 20 transcripts (see Table 2).
Some of these transcripts are from unknown genes; in these cases
we looked up the sequences and blatted against the rat genome
on the UCSC Genome Browser (RGSC 6.0/rn6). In all instances
these sequences mapped immediately downstream of a known
rat gene (see Table 2).
Next, we looked up the corresponding human orthologs in the
PGC samples to see single-nucleotide polymorphism association
results from the PGC schizophrenia GWAS27 (see Table 3). We
deﬁned start and stop for the single-nucleotide polymorphism
lookup region for each gene 20 kb from the end of the RefSeq
sequence reaching furthest in each direction. Using the total
number of PGC single-nucleotide polymorphisms within each
lookup region, we calculated gene-wide signiﬁcance as the
P-value for the most signiﬁcantly associated marker multiplied
with number of markers in the gene lookup region. We found
markers reaching gene-wide signiﬁcance at 4 out of the 20 lookup
regions: SF3B1, FOXP1, DLG2 and VGLL4. For three of these genes
(SF3B1, DLG2 and FOXP1) we observe single marker associations
reaching signiﬁcance levels close to or even surpassing the
threshold for genome-wide signiﬁcance (Table 3).
We also looked in a genome-wide typed schizophrenia
case–control sample for deletions and duplications affecting
any of the 20 human genes and found one duplication in ROBO1
in a schizophrenia subject (chr3:79098154-79280400), and
two deletions at DLG2, one in a schizophrenia subject and the
other in a control individual (chr11:82698224-82899038 and
chr11:83450214-83671604, respectively).
DISCUSSION
Although GWASs provide a powerful hypothesis-free strategy for
identifying genetic variations underlying disease and other traits,
they require associations to reach above the high threshold of
genome-wide signiﬁcance (usually P= 1 × 10− 7–1 × 10− 8) to be
regarded as true because of the large number of markers tested.
This requirement likely excludes many real association signals—
along with statistical noise—some of which could be identiﬁed by
applying a hypothesis-driven ﬁlter that would preclude many
irrelevant genes/markers from the GWAS and thus lower the
required signiﬁcance threshold.
The use of NMDA receptor antagonists such as phencyclidine,
ketamine and MK801 is a well-established method to model a
psychosis-like state in rodents.31,39 The rat model used in this
study was shown previously to express psychosis-related symp-
toms on molecular, physiological, cellular and behavioral levels.31
In the current study, we looked at differences in expression on a
whole-transcriptome level in the hippocampus of this animal
model. Our working hypothesis is that psychosis-like symptoms
induced by chronic partial blocking of NMDA receptors are at least
in part mediated by altered gene expression in brain regions such
as the hippocampus—investigated here—and, consequently, that
genetic variation affecting the expression of human orthologs of
these genes can inﬂuence risk of developing schizophrenia in
humans. To test this hypothesis, we have identiﬁed the most
markedly differentially expressed transcripts between the hippo-
campi of the MK801-treated animals and control animals, and
subsequently looked at evidence from the largest meta-analysis of
schizophrenia GWAS published to date to see whether markers in
these genes associate with schizophrenia in humans. We also
looked for CNVs at these gene loci in a case–control sample, as
deletions, duplications and disruptions (partial exonic deletions or
duplications) of genes have in many cases been shown to alter
their expressions, usually in a dosage-dependant manner.
Following several steps aimed at identifying truly differentially
expressed genes between the hippocampi of MK801-treated and
control animals, we ended up with a list of 20 transcripts from the
array, corresponding to 20 rat genes, as shown in Table 2. When
looking at the PGC GWAS results for the human orthologs of these
genes, we found that four of them included markers showing
gene-wide signiﬁcant associations with schizophrenia (Table 3). As
regards rare CNVs in our own schizophrenia case–control sample,
we found two partial deletions of the DLG2 locus (one case and
Table 1. Results of an experimental approach to ﬁnd the best
threshold of magnitude (|ALR|) and probability (P) of differentially
expressed transcripts between MK801-treated and control animals
|ALR| P EXP Boot 1 Boot 2 Boot 3 FDR (%)
0.585 0.05 74 39 12 14 34.5
0.848 0.05 24 15 5 3 41.7
0.585 0.01 15 11 4 2 50.0
0.848 0.01 3 3 1 0 66.7
0.263 0.005 46 25 12 5 40.2
0.585 0.005 4 3 1 2 50.0
0.848 0.005 1 0 0 0 0.0
Abbreviations: |ALR|, absolute average log2 ratio; Boot 1–3, number of
probes surpassing the same criteria in permutation comparisons; EXP,
number of probes meeting the |ALR| and P criteria for difference in
expression between MK801- and control animals; FDR, false discovery rate.
Figure 1. Differentially expressed transcripts in the MK801 treat-
ment. Transcripts were subjected to a two-way (horizontal: genes;
vertical: samples) unsupervised clustering using GenePattern and
Euclidian distance calculations. Individual genes are denoted by
microarray probe numbers and gene symbols, *indicates when a
transcript is in close physical proximity of a gene. Gene expression
differences are color-coded (red—increased expression; blue—
decreased expression), and the intensity of the color corresponds
to the magnitude of gene expression change. Note that this panel of
genes separates the experimental and control samples into two
distinct clusters.
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one control) and one case duplication affecting the ROBO1 locus;
all three CNVs were exon-disrupting.
Candidate genes found by cross-checking expression results from
the animal model with schizophrenia GWAS
SF3B1 encodes splicing factor 3b subunit 1, a component of the
RNA splicing machinery, and mutations in the gene have been
found to underlie myelodysplastic syndromes that predispose to
leukemia.40 Besides this, Sf3b1 was shown to be prominently
involved in processes for adult neurogenesis. Neural stem cells
and neurogenesis persist in the adult mammalian brain subven-
tricular zone. Cells born in the rodent subventricular zone migrate
to the olfactory bulb where they differentiate into interneurons.
Lim et al.41 expanded the catalog of cell cycle components,
transcription factors including Sf3b1 and migration genes for adult
subventricular zone neurogenesis, and revealed RNA splicing and
chromatin remodeling as prominent biological processes for these
germinal cells.41 Furthermore, SF3B1 is associated with PQBP1
(Polyglutamine-binding protein 1), which is a highly conserved
protein associated with neurodegenerative disorders and is linked
to intellectual disability. Wang et al.42 showed that loss of
functional PQBP1 reduced SF3B1 substrate mRNA association
and led to signiﬁcant changes in alternative splicing patterns.
Depletion of PQBP1 in primary mouse neurons reduced dendritic
outgrowth and altered alternative splicing of mRNAs enriched for
functions in neuron projection development. Disease-linked
PQBP1 mutants were deﬁcient in splicing factor associations and
could not complement neurite outgrowth defects.42
Table 2. Differentially expressed sequences and the corresponding rat and human genes
Sequence ALRa s.d. Countb P Rat gene Human gene
AW528011 − 1.08 0.24 15 0.00020 Camk4c CAMK4
AW524430 − 0.91 0.57 12 0.028 Robo1c ROBO1
BF400868 − 0.86 0.53 10 0.027 Mia3 MIA3
BF394251 − 0.82 0.53 11 0.031 Dlg2 DLG2
BF393807 − 0.81 0.45 10 0.019 Smurf2 SMURF2
AI072641 − 0.78 0.52 10 0.037 Foxp1c FOXP1
AW529817 − 0.76 0.41 11 0.017 Palm2 PALM2
NM_022683 − 0.74 0.46 9 0.028 Cul5 CUL5
BI300794 − 0.73 0.34 10 0.0085 Vgll4c VGLL4
BE113314 − 0.72 0.37 10 0.013 Prdm5 PRDM5
NM_133515 − 0.71 0.27 12 0.0034 Akap5 AKAP5
AI234943 − 0.69 0.42 10 0.027 Sf3b1 SF3B1
AI179379 − 0.68 0.27 10 0.0041 Smad2c SMAD2
NM_134326 − 0.66 0.30 9 0.0080 Alb ALB
AI233106 0.69 0.27 − 10 0.0035 Tslpc TSLP
NM_134392 0.70 0.32 − 10 0.0084 Spata6 SPATA6
NM_053832 0.72 0.34 − 11 0.0085 Foxj1 FOXJ1
NM_024400 0.84 0.38 − 11 0.0077 Adamts1 ADAMTS1
AI070651 0.84 0.40 − 12 0.0092 Wipi1/Arsgc WIPI1/ARSG
BI286012 1.17 0.51 − 14 0.0066 Krt18 KRT18
aAverage log2 ratio of expression (MK801 versus control). bNumber of individual MK801- and control animal comparisons with absolute magnitude difference
(log2 ratio) of expression 40.585. cProbe maps immediately downstream of the rat refseq gene sequence in the rat genome (rn6).
Table 3. Association of differentially expressed genes with schizophrenia in the PGC sample
Gene Locus (hg19) No. of markers in PGC_SCZ52 Best marker in PGC_SCZ52 P (best marker) Locus-wide signiﬁcancea
SF3B1 Chr2:198236697-198319771 318 rs6434928 1.5 × 10− 11 4.7 × 10− 9
FOXP1 Chr3:70983864-71653140 3431 rs7372960 1.2 × 10− 7 0.00043
DLG2 Chr11:83146055-85358314 13 630 rs12294291 4.9 × 10− 7 0.0067
VGLL4 Chr3:11577540-11782242 1508 chr3_11689216_D 1.4 × 10− 5 0.021
ROBO1 Chr3:78626387-79837059 6944 rs188858898 7.4 × 10−5 0.52
AKAP5 Chr14:64912216-64961221 253 rs1980520 0.00023 0.057
PALM2 Chr9:112383067-112733756 2550 rs78341776 0.00033 0.83
SMAD2 Chr18:45339465-45477517 719 rs189158823 0.00045 0.32
CAMK4 Chr5:110539946-110840748 1685 rs117821127 0.00099 1
PRDM5 Chr4:121595928-121864013 1951 chr4_121723039_I 0.0010 1
SMURF2 Chr17:62520734-62678386 644 rs117024269 0.0014 0.92
CUL5 Chr11:107859407-107998488 753 chr11_107977411_I 0.0022 1
ARSG/WIPI1 Chr17:66235322-66473653 1395 rs149373128 0.0026 1
SPATA6 Chr1:48741043-48957880 1306 rs146859685 0.0028 1
TSLP Chr5:110385777-110433722 291 rs79283270 0.011 1
MIA3 Chr1:222771443-222861351 448 rs9441835 0.011 1
ALB Chr4:74249971-74307129 278 rs12651581 0.012 1
ADAMTS1 Chr21:28188605-28237728 350 rs181607589 0.013 1
KRT18 Chr12:53322654-53366685 270 rs113120949 0.014 1
FOXJ1 Chr17:74112414-74157380 267 rs117235875 0.014 1
Abbreviation: PGC, Psychiatric Genetics Consortium. aP multiplied by the number of markers at each locus; rs6434928, rs7372960 and rs12294291 remain
signiﬁcantly associated at Po0.05 when correcting for all 38 991 markers from the 20 tested loci.
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Interestingly, SF3B1 is one of the 108 genome-wide signiﬁcant
loci identiﬁed in the latest schizophrenia meta-analysis published by
PGC.27 In the PGC meta-analysis, this locus stretches over roughly
300-kb region (Chr2:198.2–198.5 Mb in human genome reference
build 37), in which many markers reach beyond the P=5×10− 8
threshold for genome-wide signiﬁcance, although rs6434928 shows
the strongest association. Whereas this region includes several
genes, our results point to SF3B1 as the likely candidate through
which the genetic risk for schizophrenia is conveyed.
DLG2 is a member of a family of membrane-associated
guanylate kinases, which function as scaffolding proteins at the
postsynaptic density and are involved in NMDA receptor signaling.
Recently, Kirov et al.43 found de novo CNVs disrupting DLG2 (and
other postsynaptic genes) in schizophrenia probands, and, in a
follow-up meta-analysis including published CNV studies, found
suggestive evidence for association of CNVs affecting DLG2 with
schizophrenia.43 In a more recent study on de novo SNV mutations
in schizophrenia, the same group of researchers found a de novo
splice site mutation in DLG2 in an affected proband.44 Further-
more, another DLG family gene, DLG1, is contained within a
recurrent deletion at 3q29, which is also associated with
schizophrenia.45,46 We found two exon-disrupting CNVs affecting
DLG2, but only one of them was in a case subject; therefore, in this
respect our ﬁndings are not supportive of association (although
this could be a false-negative ﬁnding as the sample studied by
Kirov et al.43 was much larger).
FOXP1 encodes a forkhead transcription factor that has been
postulated to have an important role in language development as
well as its better known family member FOXP2. Recently, de novo
mutations and deletions affecting FOXP1 were reported in subjects
with intellectual disability, autism and language impairment.47,48
VGLL4 encodes vestigial-like 4, a protein that regulates gene
expression in myocytes49 and acts as a tumor suppressor in gastric
cancer through counteracting oncogenes.50 Its function in the
brain has not been described.
Within the ROBO1 locus the strongest association with
schizophrenia in the PGC sample was P= 7.4 × 10− 5 for
rs188858898; however, as there were over 6000 markers typed
(or imputed) in this locus, the association failed to reach gene-
wide signiﬁcance. We, however, also found a duplication
disrupting ROBO1 in a schizophrenia-affected subject from our
own case–control sample. Interestingly, the International Schizo-
phrenia Consortium reported two duplications at the ROBO1 locus
in their 2008 study involving several thousand schizophrenia cases
and healthy controls: one in a case subject and the other in a
control subject (both overlapping exons).30 The ROBO1 gene
encodes an integral membrane protein that functions in axon
guidance and migration of neuronal precursor cell across the
midline in the developing brain in rodents. The function of ROBO1
in humans is less well known but it is believed to be important for
normal crossing of auditory pathways51 and has been implicated
in several disorders, including autism,52 dyslexia51 and phonolog-
ical buffer deﬁcits.53
Convergence of results?
At ﬁrst sight, the ﬁve genes highlighted as schizophrenia
candidate genes in this study seem not to converge in a common
cellular pathway. DLG2 is the only one among these genes to be
directly involved in NMDA receptor signaling and it makes an
obvious candidate for involvement in schizophrenia pathophy-
siology. Although it may seem surprising that not more genes
belonging to the NMDA receptor pathway were identiﬁed in this
study, it should be kept in mind that the stringent ﬁlters we used
allow only the most differentially expressed in the MK801-treated
animals to be taken forward to further analysis. This is because of
the limitation imposed on the study from the small number of
experimental animals. Subsequently, many genes with subtler—
although still true—differences in expression have probably been
left behind. For example, in our previous study, we found that
expression of NMDA receptor subunits was reduced in the MK801-
treated rats when testing these speciﬁcally.31
Looking closer into studies of the function of the remaining four
genes reveals several interesting coincidences. First, both FOXP1
and ROBO1 seem to be involved in the complex processes in the
brain relating to language and speech. It has long been a popular
hypothesis in schizophrenia that it co-evolved with language and
is essentially a disorder caused by loss of asymmetry between the
brain’s hemispheres, which is vital for the separation of speech
and thought, and, indeed, auditory hallucinations are among the
most common psychotic symptoms in schizophrenia (see, for
example, Crow54).
Furthermore, SF3B1 is involved in adult neurogenesis, acts as a
transcription factors and is associated with PQBP1, which is linked
to neurodegenerative disorders and intellectual disability, an
endophenotype involved in schizophrenia. Interestingly, SF3B1 is
one of the 108 genes found in the recent largest case–control
study on schizophrenia.27
In summary, we found 20 genes differentially expressed in a
MK801 rat model of schizophrenia and ﬁnd supporting evidence
for ﬁve of these genes in the large PGC schizophrenia case–control
sample and/or in CNV data from our own case–control sample.
This suggests that at least some of these genes are involved in
schizophrenia pathology, although deﬁnite conclusions cannot yet
be made because of the associative basis of the study. Particularly
interesting are SF3B1, DLG2 and FOXP1 because of the strong
association for the SF3B1 in the PGC meta-analysis and the
previous evidence implicating DLG2 and FOXP1 in schizophrenia
and other neurodevelopmental disorders. Our study will hopefully
prompt others to focus on these genes in future studies aiming to
disentangle the pathologic processes and genetic vulnerabilities
underlying schizophrenia.
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